文献速递其他结缔组织病

系统性硬化症假性肠梗阻危险因素评估

Evaluation of risk factors for pseudo-obstruction in systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2019-05-23

该回顾性队列研究纳入约翰霍普金斯硬皮病中心2003至2017年系统性硬化症患者,比较伴与不伴假性肠梗阻者的临床特征,发现高龄、男性、弥漫性皮肤病变、肌病及阿片类药物使用为假性肠梗阻的预测因素,而RNA聚合酶-3抗体呈负相关。

要点

  • 高龄、男性、弥漫性皮肤病变、肌病及阿片类药物使用与假性肠梗阻风险升高相关
  • RNA聚合酶-3抗体与假性肠梗阻风险降低相关
  • 阿片类药物可能是可干预的危险因素

核心结论

  • 在大型美国系统性硬化症队列中识别出与假性肠梗阻相关的临床特征,提示阿片类药物可能是可干预的危险因素。

研究设计与样本

  • 回顾性分析约翰霍普金斯硬皮病中心2003年2月至2017年9月系统性硬化症患者,临床数据前瞻性收集于纵向数据库。
  • 比较伴假性肠梗阻(175例)与不伴假性肠梗阻(2637例)患者的自身抗体状态及临床人口学特征,采用Cox比例风险回归识别危险因素。

主要发现

  • 多变量Cox分析显示,高龄(HR 1.02;95%CI 1.00-1.04)、男性(HR 1.75;95%CI 1.42-2.43)、弥漫性皮肤病变(HR 2.52;95%CI 1.59-3.99)、肌病(HR 1.83;95%CI 1.09-3.08)及阿片类药物使用(HR 2.38;95%CI 1.50-3.78)可预测假性肠梗阻。
  • RNA聚合酶-3抗体与假性肠梗阻呈负相关(HR 0.34;95%CI 0.17-0.66)。

临床怎么用

  • 对于具有高龄、男性、弥漫性皮肤病变、肌病或使用阿片类药物的系统性硬化症患者,可考虑早期进行假性肠梗阻的诊断评估或治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although up to 90% of systemic sclerosis (SSc) patients are affected by gastrointestinal (GI) dysmotility, the clinical phenotype of patients with pseudo-obstruction is not well-defined. We sought to identify this phenotype by studying a large cohort of SSc patients with and without pseudo-obstruction. METHODS: We performed a retrospective analysis of patients seen at the Johns Hopkins Scleroderma Center between February 2003 and September 2017. All SSc patients had clinical data prospectively collected in a longitudinal database. Cross-sectional analyses were performed comparing autoantibody status and clinical and demographic features of patients with and without pseudo-obstruction. Cox proportional hazards regression was used to identify risk factors for pseudo-obstruction. RESULTS: 175 patients with SSc had a history of pseudo-obstruction, and 2,637 SSc patients did not. After adjusting for significant variables from the univariate analysis and potential confounders, the Cox proportional hazards multivariable analysis demonstrated that older age (HR 1.02; 95%CI 1.00-1.04), male sex (HR 1.75; 95%CI 1.42-2.43), diffuse cutaneous disease (HR 2.52; 95%CI 1.59-3.99), myopathy (HR 1.83, 95%CI 1.09-3.08), and opioid use (HR 2.38; 95%CI 1.50-3.78) were predictive of pseudo-obstruction. Autoantibodies to RNA polymerase-3 were negatively associated with pseudo-obstruction (HR 0.34; 95%CI 0.17-0.66). CONCLUSION: We identified clinical features associated with pseudo-obstruction in a large US SSc cohort. This study identifies characteristics of patients with SSc who are at a higher risk of developing pseudo-obstruction and suggests that opioids may be a modifiable risk factor. These clinical features may allow for earlier diagnostic evaluation and/or therapeutic intervention for patients at risk for pseudo-obstruction.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019. PMID: 31202479. doi:10.1016/j.semarthrit.2019.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。